Hepatitis B surface antigen seroconversion is associated with favourable long-te

StephenW

     Hepatitis B surface antigen seroconversion is associated with favourable
long-term clinical outcomes during lamivudine treatment in HBeAg-negative
chronic hepatitis B patients
Journal of Viral Hepatitis
<http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01542.x/abstract>
Summary. The aims of this study were to assess hepatitis B surface antigen
(HBsAg) seroconversion and to determine its impact on the natural course of
the disease in patients with HBeAg-negative chronic hepatitis B (CHB)
during lamivudine (LMV) treatment. A total of 183 consecutive patients with
HBeAg-negative CHB who were treated with LMV were included in the study.
Data were retrospectively collected from outpatient visit charts. The
primary endpoint was HBsAg seroconversion to anti-HBs. The secondary
endpoint was to determine the development of cirrhosis. Loss of HBsAg was
confirmed in 10 patients and seroconversion to anti-HBs in nine patients
during LMV treatment or after its discontinuation. HBsAg seroconversion was
achieved on-treatment in four patients after a median treatment duration of
30 months and off-treatment in the remaining five patients in a median 61
months after LMV discontinuation. The cumulative probability of HBsAg
seroconversion increased from 0.6% at 1 year and 1.9% at 5 years to 21.5%
at 10 years of LMV during and after LMV treatment. HBsAg clearance was
preceded by undetectable serum hepatitis B virus (HBV) DNA. The majority of
the patients responding to treatment had undetectable HBV DNA levels at 24
weeks of treatment. The cumulative probability of LMV resistance increased
from 2.2% at 1 year to 37.3% at 5 years. No baseline parameter predicting
either HBsAg seroconversion or the emergence of LMV resistance was
identified. None of the patients with HBsAg seroconversion experienced
virological breakthrough or disease progression during the follow-up
period. These results indicate that HBsAg seroclearance can occur in
patients with HBeAg-negative CHB under LMV therapy and predicts better
clinical outcome.

StephenW

乙肝表面抗原的血清转换是与有利的
在拉米夫定治疗HBeAg阴性的长期临床结果
慢性乙型肝炎患者病毒性肝炎
<http://onlinelibrary.wiley.com/d ... 2.x/abstract&gt;
摘要。这项研究的目的是评估乙肝表面抗原
（HBsAg）的血清转换，并确定其自然病程的影响
在HBeAg阴性慢性乙型肝炎（CHB）患者疾病
在拉米夫定（LMV）治疗。一共有183例
与LMV治疗的HBeAg阴性慢性乙型肝炎的研究被列入。
资料进行回顾性收集从门诊就诊图表。 “
主要终点是乙肝表面抗原血清学转换的抗- HBs。二级
终点是确定肝硬化的发展。 HBsAg消失
9例证实10例，血清转换到抗- HBs
LMV治疗期间或停药后。乙肝表面抗原血清学转换
在4例患者治疗后平均治疗时间的实现
30个月，其余5例患者治疗中位数61关闭
个月后LMV停止。 HBsAg的累积概率
血清转换增加在5年内从1年的0.6％和1.9％至21.5％
LMV治疗期间和之后，在10年的LMV。 HBsAg清除，
之前无法检测血清乙型肝炎病毒（HBV）DNA。多数
应对治疗的患者有24检测不到HBV DNA水平
周的治疗。累积的LMV耐药的概率增加
从1年的2.2％到5年的37.3％。没有基线参数预测
无论是乙肝表面抗原血清学转换的LMV耐药性的出现
确定。经验丰富的与HBsAg血清转换的患者没有
在后续的病毒学突破或病情恶化
时期。这些结果表明，乙肝表面抗原seroclearance，可发生在
下LMV治疗的HBeAg阴性慢性乙型肝炎患者和预测，更好地
临床结果。

ybdn

老外也有关注拉米与S抗原转化关系的，老王不寂寞啦

StephenW

回复 ybdn 的帖子

"累积的LMV耐药的概率增加从1年的2.2％到5年的37.3％。没有基线参数预测无论是乙肝表面抗原血清学转换的LMV耐药性的出现确定。"- 这个老王寂寞啦.

所有的医生和病人都注意在治疗(使用任何形式的药物)过程中乙肝表面抗原血清学转换. 老王不寂寞啦